PIK
Kidpik Corp.·Consumer Cyclical
2.38
100.000%(+2.38)
Market ClosedLast Updated: — ET
52W L: $2.3852W H: $3.17
PIK NEWS
prnewswire.com
4d ago
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- Hercules Capital (NYSE: HTGC) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Hercules securities between May 1, 2025 and February 27, 2026. The lawsuit follows Hunterbrook Media's critical report, "The Myth of Hercules Capital," which in part claims that Hercules' sourcing process for deals merely copies those published on Google Ventures' website.
prnewswire.com
Apr 3
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- Hercules Capital (NYSE: HTGC) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Hercules securities between May 1, 2025 and February 27, 2026. The lawsuit follows Hunterbrook Media's critical report, "The Myth of Hercules Capital," which in part claims that Hercules' sourcing process for deals merely copies those published on Google Ventures' website.
prnewswire.com
Apr 1
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Hercules Capital (NYSE: HTGC) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Hercules securities between May 1, 2025 and February 27, 2026. The lawsuit follows Hunterbrook Media's critical report, "The Myth of Hercules Capital," which in part claims that Hercules' sourcing process for deals merely copies those published on Google Ventures' website.
globenewswire.com
Feb 3
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
